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In order to characterize the genetic architecture of epilepsy in a pediatric population
from the Iberian Peninsula (including the Canary Islands), we conducted targeted
exome sequencing of 246 patients with infantile-onset seizures with or without
neurodevelopmental delay. We detected 107 variants in 48 different genes, which
were implicated in neuronal excitability, neurodevelopment, synaptic transmission, and
metabolic pathways. In 104 cases (42%) we detected variant(s) that we classified as
pathogenic or likely pathogenic. Of the 48mutated genes, 32 were dominant, 8 recessive
and 8 X-linked. Of the patients for whom family studies could be performed and in
whom pathogenic variants were identified in dominant or X-linked genes, 82% carried
de novo mutations. The involvement of small copy number variations (CNVs) is 9%.
The use of progressively updated custom panels with high mean vertical coverage
enabled establishment of a definitive diagnosis in a large proportion of cases (42%)
and detection of CNVs (even duplications) with high fidelity. In 10.5% of patients we
detected associations that are pending confirmation via functional and/or familial studies.
Our findings had important consequences for the clinical management of the probands,
since a large proportion of the cohort had been clinically misdiagnosed, and their
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families were subsequently able to avail of genetic counseling. In some cases, a more
appropriate treatment was selected for the patient in question, or an inappropriate
treatment discontinued. Our findings suggest the existence of modifier genes that may
explain the incomplete penetrance of some epilepsy-related genes. We discuss possible
reasons for non-diagnosis and future research directions. Further studies will be required
to uncover the roles of structural variants, epimutations, and oligogenic inheritance
in epilepsy, thereby providing a more complete molecular picture of this disease. In
summary, given the broad phenotypic spectrum of most epilepsy-related genes, efficient
genomic tools like the targeted exome sequencing panel described here are essential for
early diagnosis and treatment, and should be implemented as first-tier diagnostic tools
for children with epilepsy without a clear etiologic basis.
Keywords: epilepsy, genetic diagnosis, neurodevelopmental disorders, de novo mutations, incomplete
penetrance, modifier genes
INTRODUCTION
Epilepsy is one of the most common neurological conditions,
with a prevalence of ∼1%. Etiological diagnosis of epilepsy in
children using classical diagnostic tools is often a long and
complex process. Moreover, most patients undergo multiple
invasive and costly analyses but do not receive conclusive
molecular diagnosis.
The emergence of next generation sequencing (NGS)-
based tools has helped address the diagnostic challenge posed
by epilepsy. These approaches allow genetic analyses to be
performed faster, less expensively, and at much higher resolution.
This technology has also helped identify many novel genes
involved in epilepsy phenotypes.
In recent years several articles have described the use of
targeted NGS or whole-exome sequencing (WES) to diagnose
epileptic patients, with varying diagnostic yields. The results of
these studies have helped characterize the molecular landscape
of epilepsy, and indicate that infantile onset epilepsy is caused
by a wide spectrum of genes, most of which are de novo
variants in dominant genes (Epi4K Consortium et al., 2013;
EuroEPINOMICS-RES Consortium, 2014; Allen et al., 2016),
although a minority of recessive genes are also implicated.
Mosaic mutations and copy number variants (CNVs) are other
important sources of mutations in epileptic disorders (Gennaro
et al., 2006; Vadlamudi et al., 2010; de Lange et al., 2017).
CNVs can cause epilepsy through the deletion or duplication
of known epilepsy-related genes. Moreover, the presence of
epilepsy-related genes in genomic regions affected by deletions
can give rise to complex syndromic conditions (Wang et al.,
2008; Dibbens et al., 2009; Helbig et al., 2009; de Kovel et al.,
2010; Heinzen et al., 2010; Dejanovic et al., 2014; Epilepsy
Phenome/Genome Project Epi4K Consortium, 2015; Mefford,
2015; Borlot et al., 2017; Tsuchida et al., 2018).
Recently Oates et al. (2018) demonstrated that early gene
panel screening of newborns with epilepsy could reduce the
cost of subsequent tests from $9,362 to $2,838 and the median
diagnostic delay from 3.43 years to 21 days. Gene panel testing for
epilepsy has a high diagnostic yield among children with onset
before 2 years of age, and an appreciable clinical, social, and
financial impact.
In cases of children with epilepsy, establishing a molecular
diagnosis in a clinical setting is essential to (1) establish
the risk of recurrence in subsequent pregnancies; (2) end
the all-too-common diagnostic odyssey endured by parents
of undiagnosed children; (3) avoid unnecessary analyses and
treatments; (4) provide an accurate prognosis; (5) optimize
management; (6) provide a prenatal or preimplantation diagnosis
for future pregnancies; (7) identify, at least in some cases, specific
appropriate therapies and enable the application of precision
medicine as targeted therapeutics emerge.
The importance of genomic analyses in epilepsy has been
previously discussed in depth (Lemke et al., 2012; Mercimek-
Mahmutoglu et al., 2015; Mei et al., 2017; Weber et al., 2017).
In this study, we present a comprehensive description of the
molecular signature of pediatric epilepsy patients of Iberian
origin and discuss the results obtained.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of the
Hospital Santiago de Compostela (Spain). A total of 246 patients
were recruited over a 5-year period from different neurologic
units in Spain and Portugal, applying the following inclusion
criteria: patients with any condition in which seizures are
either the sole clinical expression or are part of more severe
neurodevelopmental disorder.
Panel Design
Successive Epi-panels were constructed using OMIM-registered
genes for which the associated clinical picture included seizures.
In addition, we conducted a thorough review of the most recent
scientific publications to identify genes associated with any form
of epilepsy, with or without neurodevelopmental delay. We
included genes for which only one published report was found,
even if the involvement was suspected but not demonstrated. The
selection of genes included the panel was regularly evaluated and
updated throughout the study period to ensure the inclusion of
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all novel genes reported in the literature. Each Epi-panel included
all exons and at least 25 base pairs of the flanking intronic
sequence of the selected genes. A list of the genes included in
the consecutive versions of each panel can be provided upon
request. The first panel consisted of 88 genes and final version
274 genes. This increase reflects the high rate of discovery of
epilepsy-associated genes in recent years. Because the analyses
conducted at the beginning of this project were done so using
comparatively incomplete panels, all undiagnosed patients who
provided consent were re-analyzed at the end of the study using
the most up-to-date panel in order to rule out as many false
negatives as possible.
Targeted Next Generation Sequencing
Enrichment was performed using in-solution hybridization
technology (Sure Select XT; Agilent Technologies, Santa Clara,
California) and subsequent sequencing using Miseq or NextSeq
platforms (Illumina, Santa Clara, California), as previously
described (Fernández-Marmiesse et al., 2018). Image analysis
and processing of the fluorescence intensities in sequences
(“base calling”) was performed with Real Time Analysis (RTA)
software v.1.8.70 (Illumina), and FastQC v0.11.8 program was
used for data quality control (Babraham Bioinformatics-FastQC
A Quality Control Tool for High Throughput Sequence Data,
2018). Reads were aligned to the reference genome GRCh37
with BWA v0.7.17 (Li and Durbin, 2009), and BEDTools 2.27.1
(Quinlan and Hall, 2010) and Picard v2.18.14 (Picard Tools-
By Broad Institute, 2018) were used for intermediate steps.
VarScan v.2.4.2 (Koboldt et al., 2009), SAMtools v1.9 (Li et al.,
2009), GATK v4.0.10 (McKenna et al., 2010), Pindel v0.2.5
(Ye et al., 2009), and Platypus v0.8.1 (Rimmer et al., 2014)
software were used for variant detection, SnpEff v4.3 (Cingolani
et al., 2012) for variant annotation, and PattRec for CNV
detection (Roca et al., 2019).
Variants that passed the quality control step were prioritized
according to their minor allele frequencies (MAF < 0.01) in
the following databases: 1000G, Exome Aggregation Consortium
(ExAC), the Exome Variant Server (EVS), the Genome
Aggregation Database (gnomAD), and our in-house population
database (onwards IberDB). Z-score was used to evaluate the
conservation of genes which harbor rare/low-frequency variants
(Roca et al., 2018). Possible pathogenicity of the missense
variants detected was assessed using the in silico tools CONDEL
(González-Pérez and López-Bigas, 2011), GERP++ (Davydov
et al., 2010), and Human Splicing Finder (HSF 3.0) (Desmet et al.,
2009). Variants were classified as “pathogenic” or “of uncertain
significance” in accordance with the guidelines of the American
College of Medical Genetics and Genomics (ACMG) (Richards
et al., 2015).
Statistical Analyses
The variants used for all calculations (unless otherwise stated)
were those recorded in 2,504 individuals enrolled in Phase 3 of
the 1000 Genomes Project (1000G) and in 125,748 individuals
whose data are included in v2.1.1 of the Genome Aggregation
Database (gnomAD). Variants classified as “pathogenic” or
“likely pathogenic” in the ClinVar database were filtered out.
The mutation tolerance of each epilepsy-associated gene was
quantified by determining the corresponding z-score (Roca et al.,
2018). This score was calculated by first regression of the total
number of missense variants against the total number of missense
and synonymous variants observed for a given gene. The z-
score is the corresponding studentized residual of the regression.
Genes with a negative z-score have fewer missense variants than
expected based on the expected mutation burden and are likely
to be less tolerant of functional mutations.
To determine the probability of detecting 2 rare variants in
1 gene, or 1 rare variant in 2 genes simultaneously, we used
the Poisson distribution, P(λ), for each scenario, where λ is the
frequency of samples fulfilling those conditions. Only missense
variants from 1000G with a MAF< 0.5% were considered.
RESULTS
The median (interquartile range) coverage of the samples
analyzed with successive versions of the Epi-panel was
392X (309X−461X). The overall target coverage at 10X
of the genes included in the successive versions of the
Epi-panel ranged from 97.3 to 99.85%. However, mean
target coverage increased over time, reaching 98.1–99.7%
for the last 3 versions, indicating progressive optimization
of the test. The regions missed were almost identical
across the different samples, and shared a high GC
content, repeat elements, or homology with other parts of
the genome.
To prioritize the rare missense variants and assign them a
higher or lower weight in terms of their contribution to the
patient’s phenotype we examined gene tolerance to missense
variation (z-score) for all epilepsy-associated genes in Iberian
patients. The results are shown in Figure 1.
Figures 2A,B show the statistical comparison of GERP and
CONDEL scores for variants detected in our cohort with those
of other missense variants found in the same genes in controls
(extracted from 1000G and gnomAD databases). It is important
to highlight that, of the missense variants found in the genes in
the databases, MAF values were<0.01 in 94.88% of cases,<0.005
in 92.57% of cases, and<0.001 in 85% of cases.
We detected variants in 52 different genes. Of these, 17 were
involved in neuronal excitability, 30 in neurodevelopment and
synaptic transmission, and 5 in metabolic pathways. Variants
found in our cohort are shown in Tables 1A,B. For 32 genes
(65%) variants were detected in 1 single patient, and for the
following 7 genes variants were detected in more than 2 patients
each: SCN1A (16 patients), KCNQ2 (13 patients), CDKL5 (7
patients), SCN2A (4 patients), MECP2 (4 patients), GNAO1 (4
patients), and FOXG1 (3 patients). In 42% of cases the mutation
identified was considered pathogenic or likely pathogenic and
the main cause of patient’s phenotype (Table 1A). In 10.5% of
cases prioritized variants were classified as potentially involved
(Table 1B), but further evidence will be required to confirm this
association. It is important to note that in 9 cases variants could
not be classified as pathogenic or non-pathogenic owing to a lack
of variant analysis data from the progenitors required to confirm
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FIGURE 1 | Z-score for each gene in Table 1, calculated as described in the section Material and Methods. AD, autosomal dominant inheritance; AR, autosomal
recessive inheritance; X-linked: X-linked inheritance.
or rule out de novo events. Figure 3 shows the proportions of
different types of inheritance and different types of variants.
The clinical features of the patients carrying the variants that
appear in Tables 1A,B are listed in the Supplementary Table 1.
The locations of the variants in some of the genes are shown
in Figures 4, 5. The position of 2 CNVs in FOXG1 and GPHN
relative to those previously reported is shown in Figure 6.
DISCUSSION
Utility of Z-Score and GERP and CONDEL
Scores for Variant Prioritization
We found that z-score and GERP and CONDEL scores can be
combined to provide an effective means of assessing the potential
pathogenicity of variants detected in epilepsy patients.
A negative z-score implies a marked sensitivity to missense
variation, and indicates that missense variations in these
genes are much more likely to affect the function of the
encoded proteins. The genes most sensitive to missense
variation were KCNT1, TSC2, and MTOR (Figure 1). However,
the variants detected in these 3 genes in our cohort were
classified as “of uncertain significance,” as explained below. The
next most sensitive genes were 3 ion-channel-encoding genes
(SCN2A, SCN8A, KCNQ2), mutations in which are found in
a significant percentage of patients with neurodevelopmental
problems. A higher z-score indicates a lower sensitivity
to missense variation. For example, WWOX (z-score >
3) is a recessive gene with low sensitivity to missense
changes. In fact, most disease-associated mutations described
for this gene are truncating mutations (Shaukat et al., 2018).
SCN10A and RFT1 are recessive genes and therefore had the
highest z-scores.
As shown in Figures 2A,B, GERP and CONDEL scores
constitute a useful means of discriminating between innocuous
and deleterious variants. For some highly conserved genes
(MTOR, SCN2A, SCN8A, KCNA2, SCN1A, DNM1, KCNC1,
GNAO1, STXBP1, GRIN2A, HCN1, NPRL2), we observed
very high mean GERP values and low variability (Figure 2A).
Any missense variation in these genes can be considered
potentially deleterious. For other genes (KCNQ2, SLC13A5,
KCNT1, PROSC) the range of GERP scores was much
wider, implying that some nucleotides are much more
sensitive to variation than others, and therefore that in
addition to CONDEL score the location of the variant
is important.
As shown in Figure 2B, CONDEL score allowed effective
discrimination between deleterious and innocuous variants for
the 2 most mutated genes in our cohort: KCNQ2 and SCN1A
(p = 2.8e−5 and 1.12e−6, respectively; Wilcoxon test). In
general, for all variants shown in Table 1A, CONDEL scores
were above the upper limit of distribution of the control
variants (yellow bars), except for 2 variants in RFT1 (recessive)
and CDKL5 (X-linked). Interestingly, both these variants had
very high GERP scores. This suggests that even though the
amino acid change is functionally relatively innocuous, its
location may have a significant impact on the protein (e.g.,
from regulatory point of view), since it is highly conserved
throughout evolution.
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FIGURE 2 | (A,B) Boxplot showing GERP/CONDEL scores (median and interquartile range) for missense variants. Scores for the pathogenic missense variants
reported in Table 1 are shown in red, and scores for the missense variants found in control samples within each gene are shown in yellow. Only genes with
pathogenic missense variants are shown. Genes with autosomal dominant inheritance (AD) are shown in blue, genes with autosomal recessive inheritance (AR) in red,
and genes with X-linked inheritance in green.
Variants Classified as Pathogenic and
Likely Pathogenic
Most Mutated Genes
We detected 23 variants in SCN1A (Tables 1A,B and Figure 3A),
including a long duplication that encompassed the sodium
channel cluster (2q24.3) and was confirmed by array comparative
genomic hybridization (CGH). Of the 23 SCN1A variants
detected 16 were considered highly likely to contribute to the
patient’s phenotype (Table 1A). As previously noted in other
studies, missense variants in this gene were associated with
milder phenotypes, except for those located in the pore region of
the channel. We also found that phenotype severity was inversely
proportional to familial incidence (Meng et al., 2015).
Six patients carried SCN2A variants, but only 4 were classified
as pathogenic or likely pathogenic (Figure 4B). As expected, the
2 SCN2A truncating variants were associated with a late-onset
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TABLE 1A | Variants considered highly likely to be implicated in the patient’s phenotype.
P S GENE INH ZIG VFS FH ClinVar dbSNP ID MAF Type ISP GERP Ref Seq Variant
52 F SCN1A AD HT DE NOVO – LP rs121917945 – MISS 0.73 5.29 NM_001165963.1 c.4352C>T; p.P1451L
71 F SCN1A-
2A
AD HT DE NOVO – – – – CNV - - NC_000002.11 g. (?_166093912)_
(167343501_?)dup
406 F SCN1A AD HT DE NOVO – – – – NON - 5.08 NM_001165963.1 c.2728C>T; p.Q910X
528 F SCN1A AD HT NA – P/LP rs121918624 – NON - 5.77 NM_001165963.1 c.664C>T; p.R222X
548 F SCN1A AD HT MAT + CIP rs121917922 – MISS 0.61 5.27 NM_001165963.1 c.4973C>T; p.T1658M
597 F SCN1A AD HT DE NOVO – P/LP rs794726760 – MISS 0.76 5.27 NM_001165963.1 c.4997C>T; p.S1666F
651 M SCN1A AD HT DE NOVO – P/LP rs121918624 – NON - 5.77 NM_001165963.1 c.664C>T; p.R222X
652 M SCN1A AD HT NA – P/LP rs121917915 – MISS 0.78 5.9 NM_001165963.1 c.4822G>T; p.D1608Y
829 M SCN1A AD HT MAT + – – – MISS 0.68 5.79 NM_001165963.1 c.5456C>A; p.A1819E
832 M SCN1A AD HT DE NOVO – – – – MISS 0.72 4.57 NM_001165963.1 c.C338G; p.P113R
716 F SCN1A AD HT DE NOVO – – – – FS - 4.9 NM_001165963.1 c.2020_2023del; p.
(D674Sfs*15)
860 F SCN1A HT DE NOVO – – – – MISS 0.74 5.24 NM_001165963.1 c.493T>C; p.Y165H
937 M SCN1A AD HT NA – P rs121917971 – MISS 0.72 5.18 NM_001165963.1 c.2837G>A; p.R946H
980 M SCN1A AD HT NA + P rs121918783 – MISS 0.68 4.43 NM_001165963.1 c.5555T>C; p.M1852T
1112 M SCN1A AD HT PAT + – – – MISS 0.76 5.27 NM_001165963.1 c.5009T>C; p.L1670S
1198 M SCN1A AD HT DE NOVO – – – – MISS 0.73 5.9 NM_001165963.1 c.4658T>C; p.L1553P
314 F SCN2A AD HT NA – P/LP rs796053138 – NON - 0.244 NM_001040142.1 c.4303C>T; p.R1435*
759 F SCN2A AD HT DE NOVO – P/LP rs796053126 – MISS 0.68 5.69 NM_001040142.1 c.2995G>A; p.E999K
781 M SCN2A AD HT NA + – – – MISS 0.57 5.5 NM_001040142.1 c.G5117C; p.C1706S
1235 M SCN2A AD HT NA – – – – NON - 5.59 NM_001040142.1 c.2469G>A; p.W823*
660 M SCN8A AD HT DE NOVO – – – – MISS 0.67 4.45 NM_014191.3 c.2620G>A; p.A874T
1173 M SCN10A AR HT NA – – rs747321219 8.1E+00 FS NA 1.16 NM_006514.3 c.5694delA; p.
(A1899Qfs*36)
SCN10A HT NA – – rs774337248 1.2E+00 MISS 0.76 4.14 NM_006514.3 c.3800T>G; p.M1267R
9 F KCNQ2 AD HT DE NOVO – P rs864321712 - MISS 0.65 3.89 NM_172107.3 c.319C>T; p.L107F
26 F KCNQ2 AD HT DE NOVO – P rs759584387 8.9E-106 MISS 0.67 1.62 NM_172107.3 c.1657C>T; p.R553W
90 M KCNQ2 AD HT DE NOVO – CIP rs727503974 – MISS 0.75 4.01 NM_172107.3 c.821C>T; p.T274M
91 F KCNQ2 AD HT DE NOVO – P rs864321710 – MISS 0.67 3.61 NM_172107.3 c.388G>A; p.E130K
155 F KCNQ2 AD HT DE NOVO – LP rs864321707 – MISS 0.65 4.01 NM_172107.3 c.917C>T; p.A306V
158 M KCNQ2 AD HT DE NOVO – P rs864321706 – MISS 0.63 4.01 NM_172107.3 c.850T>G; p.Y284D
475 F KCNQ2 AD HT DE NOVO – – – – MISS 0.57 3.38 NM_172107.3 c.778C>T; p.H260Y
485 F KCNQ2 AD HT NA – – – – MISS 0.65 4.01 NM_172107.3 c.829A>T; p.T277S
571 M KCNQ2 AD HT DE NOVO – P rs886041262 – MISS 0.60 4.05 NM_172107.3 c.629G>A; p.R210H
704 F KCNQ2 AD HT DE NOVO – LP rs1057523728 – MISS 0.58 4.01 NM_172107.3 c.833T>C; p.I278T
744 F KCNQ2 AD HT NA – LP rs897976020 1.23E-
105
MISS 0.64 5.37 NM_172107.3 c.1588G>A; p.E530K
875 M KCNQ2 AD HT PAT + – – – MISS 0.64 4.34 NM_172107.3 c.1016T>A; p.L339Q
1085 M KCNQ2 AD HT DE NOVO – P rs118192234 – MISS 0.67 4.99 NM_172107.3 c.1658G>A; p.R553Q
84 M KCNQ3 AD HT NA + – – – MISS 0.68 5.51 NM_004519.3 c.899T>C; p.F300S
868 F KCNA2 AD HT DE NOVO – – – – MISS 0.64 5.87 NM_004974.3 c.959C>T; p.T320I
109 M KCNB1 AD HT DE NOVO – – – – MISS 0.74 6.02 NM_004975.3 c.1107G>C; p.W369C
41 M KCNT1 AD HT TRANS – – – – SP - 5.24 NM_020822.2 c.3503-1G>A
KCNT1 AD – P – – MISS 0.61 4.87 NM_020822.2 c.785G>A; p.R262Q
957 M KCNT1 AD HT NA – P – – MISS 0.61 4.87 NM_020822.2 c.785G>A; p. R262Q
1068 M KCNC1 AD HT NA – – – – MISS 0.74 4.41 NM_001112741.1 c.88C>T; p.P30S
501 M SLC12A5 AR HO TRANS – – – – MISS 0.59 3.47 NM_001134771.1 c.3274G>A; p.E1092K
901 M CLCN4 XL HE MAT + – – – MISS 0.55 5.69 NM_001830.3 c.1576G>A; p.G526S
1177 M CLCN4 XL HE NA – – – – MISS 0.62 5.25 NM_001830.3 c.1597G>A; p.V533M
658 M HCN1 AD HT DE NOVO – LP rs1057519547 – MISS 0.69 5.42 NM_021072.3 c.1172G>A; p.G391D
(Continued)
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TABLE 1A | Continued
P S GENE INH ZIG VFS FH ClinVar dbSNP ID MAF Type ISP GERP Ref Seq Variant
67 M SLC13A5 AR HT TRANS – – rs1211773372 – FS - 3.12 NM_177550.4 c.1511delT; p. (L504Cfs*23)
SLC13A5 HT – – rs936922976 – MISS 0.54 5.15 NM_177550.4 c.1514C>T; p.P505L
1030 F FGF12 AD HT NA – P rs886039903 – MISS 0.65 5.51 NM_021032.4 c.341G>A; p.R114H
37 F PRRT2 AD HT NA + – – CNV - - NC_000016.10 g. (?_29824300)_
(29826034_?)del
207
629
975,
1129
F PRRT2 AD HT NA + P rs587778771 0.007 FS - 3.9 NM_001256442.1 c.649_650insC; p.
(R217Pfs*8)
545 F ARX XL HT DE NOVO – – – – MISS 0.74 3.87 NM_139058.2 c.1039T>G; p.F347V
385 M MECP2 XL HE DE NOVO – – – – NON - 5.67 NM_001110792.1 c.1386C>G; p.Y462X
474 F MECP2 XL HT NA – P rs886041728 – FS - 5.11 NM_001110792.1 c.1087_1088insC; p.
(K363Tfs*30)
572 M MECP2 XL HE NA – P/LP rs61751443 – MISS 0.52 5.06 NM_001110792.1 c.917G>A; p.R306H
965 F MECP2 XL HT NA – – – – NON - 5.8 NM_001110792.1 c.1453G>T; p.E485*
420 F FOXG1 AD HT NA – – – – NON - 4.05 NM_005249.4 c.764G>A; p.W255X
427 M FOXG1 AD HT DE NOVO – P/LP rs398124202 - NON - 2.03 NM_005249.4 c.256C>T; p.Q86X
872 M FOXG1 AD HT DE NOVO – – – – MISS 0.68 3.09 NM_005249.4 c.565C>T; p.L189F
47 F CDKL5 XL HT DE NOVO – – – – MISS 0.67 5.69 NM_001037343.1 c.176G>C; p.R59P
131 F CDKL5 XL HT DE NOVO – – – – MISS 0.50 6.07 NM_001037343.1 c.455G>A; p.C152Y
156 F CDKL5 XL HT DE NOVO – – – – FS - −0.27 NM_001037343.1 c.2635_2636del; p.
(L879Efs*30)
202 F CDKL5 XL HT DE NOVO – LP rs267608433 – FS - 4.59 NM_001037343.1 c.163_166del; p.
(E55Rfs*20)
472 M CDKL5 XL HE DE NOVO – P/LP rs267608659 – NON - 6.03 NM_001037343.1 c.2413C>T; p.Q805X
473 F CDKL5 XL HT DE NOVO – – – – MISS 0.39 6.1 NM_001037343.1 c.616G>T; p.E206Y
1127 F CDKL5 XL HT NA – – – – MISS 0.75 5.98 NM_001037343.1 c.380A>T; p.H127L
310 M HNRNPU AD HT DE NOVO – – – – FS - 4.34 NM_031844.2 c.401_402delAC; p.
(D134Gfs*10)
421 M TBC1D24 AR HO TRANS – P/LP rs398122965 1.5E-105 MISS 0.50 4.2 NM_001199107.1 c.724C>T; p.R242C
317 F GNAO1 AD HT DE NOVO – P rs587777057 – MISS 0.73 5.28 NM_020988.2 c.607G>A; p.G203R
684 F GNAO1 AD HT DE NOVO – P rs1064794533 – MISS 0.74 5.29 NM_020988.2 c.709G>A; p.D237L
1208 F GNAO1 AD HT DE NOVO – P rs587777057 – MISS 0.73 5.28 NM_020988.2 c.607G>A; p.G203R
606 M GNAO1 AD HT NA – – – – MISS 0.52 4.24 NM_138736.2 c.901G>C; p.V301L
289 M CSNK2B AD HT DE NOVO – – rs1339457069 0 NON - 4.88 NM_001320.6 c.124C>T; p.Gln42*
164 M SLC9A6 XL HE DE NOVO – – – – NON - 5.36 NM_001042537.1 c.1601C>G; p.S534*
1238 M WWOX AR HT TRANS – – – – NON - - NM_016373.3 c.1114G>T; p.G372*
WWOX HT – – – – CNV - - NG_011698.1
(NM_016373.3)
c. (605+1_606-
1)_(791+1_792-1)del
996 M NPRL2 AD HT PAT + – – – MISS 0.78 5.17 NM_006545.4 c.949G>A; p.G317R
1213 M NPRL3 AD HT NA + – – – NON NA NM_001077350.2 c.138delC; p.W46*
951 M DEPDC5 AD HT EN
CURSO
– – – – CNV - - NG_034067.1
(NM_001242896.1)
c. (1081+1_1082-
1)_(1143+1_1144-1)del
782 M SRGAP2 AD HT NA – – – – CNV - - NG_033804.1
(NM_015326.4)
c. (?_0)_(570+1_571-1)dup
c. (897+1_898-
1)_(*3018_?)dup
519 M RBFOX1 AD HT PAT – – – – CNV - - NG_011881.1
(NM_001308117.1)
c. (3+1_4-1)_(114+1_115-
1)del
530 M GPHN AD MAT – – – – CNV - - NG_008875.1
(NM_020806.4)
c. (143+1_144-
1)_(294+1_295-1)del
819 M GPHN AD HT MAT – – – – CNV - - NG_008875.1
(NM_020806.4)
c.
(143+1_144-1)_(*871_?)del
186 F ARHGEF9 XL HT DE NOVO – – – – MISS 0.79 5.65 NM_015185.2 c.541G>C; p.G181R
(Continued)
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TABLE 1A | Continued
P S GENE INH ZIG VFS FH ClinVar dbSNP ID MAF Type ISP GERP Ref Seq Variant
1126 M SLC6A1 AD HT NA – – – – MISS 0.69 4.21 NM_003042.3 c.373G>A; p.V125M
1156 F SLC6A1 AD HT DE NOVO – – – – MISS 0.69 5.57 NM_003042.3 c.1153T>C; p.F385L
1058 M IL1RAPL1 XL MOS DE NOVO – – – – CNV - - NG_008292.1
(NM_014271.3)
c. (?_−24)_(1057+1_1058-
1)del
598 M STXBP1 AD HT DE NOVO – P/LP rs796053353 – MISS 0.72 5.71 NM_003165.3 c.416C>T; p.P139L
1214 M STXBP1 AD HT NA – P rs796053361 – MISS 0.78 4.75 NM_003165.3 c.875G>A; p.R292H
1233 F STXBP1 AD HT DE NOVO – – – – SPL NA 5.62 NM_003165.3 c.1548-2A>G
201 F DNM1 AD HT DE NOVO – US rs751244420 5.4E-105 MISS 0.50 1.83 NM_025014.1 c.112G>A; p.G38S
481 M DNM1 AD HT DE NOVO – – – – MISS 0.71 5.42 NM_001288739.1 c.442C>A; p.Q148L
740 M SYN1 XL HE MAT + – – – MISS 0.59 4.01 NM_006950.3 c.376T>A; p.W126R
218 F GRIN2A AD HT DE NOVO – – rs1445802934 8.9E-106 MISS 0.45 5.65 NM_000833.4 c.2069C>T; p.T690M
857 F ARHGEF15 AD HT NA – – – – NONFS - −0.65 NM_025014.1 c.709_723del;
p.Val237_Ala241del
685 M RHOBTB2 AD HT DE NOVO – – – – MISS 0.62 5.08 NM_001160036.1 c.1531C>T; p.R511W
904 M GABRG2 AD HT PAT + – – – NON - 5.56 NM_198903.2 c.824G>A; p.W275*
76 M SYNGAP1 AD HT DE NOVO – – – – NON - 4.8 NM_006772.2 c.1264G>T; p.E422*
859 F SLC35A2 AD HT NA – – – – FS - 4.27 NM_001282651.1 c.636_657del; p.
(Q213Hfs*157)
561 M RFT1 AR HO TRANS – US rs148716754 0.003 MISS 0.54 6.03 NM_052859.3 c.47C>G; p.S16C,
1197 M DHDDS AR,AD HT DE NOVO – – – – MISS 0.79 5.72 NM_024887.3 c.110G>A; p.R37H
954 M PROSC AR HT TRANS – – rs79148472 0.005 MISS 0.43 3.19 NM_007198.3 c.157A>G; p.M53V
PROSC HT – – rs150307985 9.85E-
105
MISS 0.40 4.94 NM_007198.3 c.445G>A; p.G149R
38 M PCCA AR HT TRANS – – – – SP - 2.48 NM_000282.3 c.469-4A>G
PCCA HT – – rs146927771 0.0012 MISS 0.57 3.78 NM_000282.3 c.929C>G; p.A310G
P, patient; S, sex; M, male; F, female; INH, type of inheritance described for the gene up to now; AD, autosomal dominant; AR, autosomal recessive; XL, X-linked; ZYG, zygosity; HT,
heterozygous; HO, homozygous; HE, hemizygous; VFS, variant family study; M, maternal; PAT, paternal; Abbreviations: NA, not available; FH, familial history; ClinVar, classification in the
variant in ClinVar database; P, pathogenic; LP, likely pathogenic; US, uncertain significance; B, benign; LB, likely benign; dbSNP, ID in Single Nucleotide Polymorphism Database; MAF,
minor allele frequency in public databases; TYPE, functional consequence; MISS, missense; NON, nonsense, SP, splicing; FS, frameshift; NONFS, nonframeshift; CNV, copy number
variant; GERP, genomic evolutionary rate profiling score; ISP, in silico prediction with CONDEL software; REFSEQ, Reference Sequence.
ASD/ID phenotype that was unresponsive to Na+ channel
blockers. Conversely, the missense variant in P759 behaved as
a gain of function (GOF) variant and was associated with early
onset and a severe seizure phenotype.
We detected 13 missense KCNQ2 variants in our cohort,
6 of the which had been previously described by our group
in an article providing extensive information on phenotype-
genotype relationship (Hortigüela et al., 2017). As expected, the
phenotypes of patients with variants located in the pore-forming
domain were severe (Figure 4C).
Seven patients from our cohort carried variants in KCNT1.
The lower z-score of this gene (Figure 1) indicates high
sensitivity to missense variation. However, owing to the variable
penetrance of variants in this gene it is difficult to demonstrate
a definitive association between these variants and the patients’
phenotypes. Patient P41 was found to carry biallelic KCNT1
mutations; one caused altered splicing and the other was a
missense variant (R262Q) previously described as a de novo
variant in an individual with malignant migrating focal seizures
of infancy. In line with the variable penetrance previously
reported for this gene, the progenitor of the patient carrying this
mutation (P41) was healthy. This is not the first case of recessive
inheritance in this gene (Martin et al., 2014; Møller et al., 2015).
The same missense pathogenic variant R262Q was detected in
P957. However, in this case it was not possible to demonstrate
a de novo event. While another missense heterozygous indel
leading to the missense change S971N was detected in P1008,
a familial study could not be performed for this particular
patient, preventing classification of the variant. Finally, variant
R474L was detected in P268. This variant was found to be
paternally inherited. Nonetheless, we consider it highly likely
that this variant contributes to the patient’s phenotype, as 3
variants affecting the same amino acid (R474S, R474C, and
R474H) are classified as disease-associated variants in the
ClinVar database (Barcia et al., 2012). The incomplete penetrance
previously described for this gene (Møller et al., 2015) remains to
be explained.
Five variants were detected in FOXG1. Of the 3 missense
variants, 2 were located in the conserved forkhead domain (FHD;
Figure 5C) where most disease-associatedmissense variants have
been found (Mitter et al., 2018). R219Gwas a paternally inherited
variant located in this key region. We observed high GERP
and CONDEL scores for this variant. However, the clinical
phenotype did not match that typically associated with FOXG1
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TABLE 1B | Variants of uncertain significance [further studies required to confirm relationship between variant(s) and patient’s phenotype].
P S GENE INH ZYG VFS FH ClinVar dbSNP MAF TYPE ISP GERP Ref seq Variant
FUNCTIONAL VALIDATION REQUIRED
248 F SCN9A AD HT TRANS – – rs180949263 0.0002 MISS 0.55 3.34 NM_002977.3 c.5672G>A/p.R1891H
SCN9A AD HT – B/LB rs202084411 0.0024 MISS 0.53 4.47 NM_002977.3 c.4612T>C/p.W1538R
CHD2 AD HT MAT – – – – MISS 0.53 5.69 NM_001271.3 c.4564G>A/p.D1522N,
918 M MTOR AD HT PAT – – rs1390645065 8.9E-106 MISS 0.52 5.89 NM_004958.3 c.7249G>A/p.V2417M
MTOR AD HT MAT – – rs201557303 0.0002 MISS 0.42 4.91 NM_004958.3 c.5197G>A/p.A1733T
1084 M MTOR AD HT PAT – – – – MISS 0.51 4.78 NM_004958.3 c.126G>T/p.K42N
1144 M TSC2 AD HT PAT – – – – MISS 0.59 5.51 NM_000548.4 c.1724T>C/p.L575P
INCOMPLETE PENETRANCE
754 M GABRB1 AD HT MAT – LP rs1135401786 – MISS 0.75 3.29 NM_000812.3 c.157C>T; p.R53W
938 F GABRB1 AD HT MAT – – – – MISS 0.53 5.43 NM_000812.3 c.775A>G/p.I259V
703 M SCN2A AD HT PAT – – – – MISS 0.67 3.68 NM_001040142.1 c.5551C>T/p.R1851W
801 F SCN1A AD HT MAT – US rs184524479 0.00019 MISS 0.49 4.33 NM_001165963.1 c.1604G>A/p.R535H
RBFOX1 AD HT MAT – – rs1287710352 8.9E-106 MISS 0.41 5.86 NM_145891.2 c.983A>G/p.K328R
1119 F SYN1 XL HT PAT – – – – MISS 0.65 4.88 NM_006950.3 c.718G>A/p.G240R
650 M FOXG1 AD HT PAT – – – – MISS 0.63 3.69 NM_005249.4 c.655C>G/p.R219G
1008 M KCNT1 AD HT MAT – – – – MISS NA 4.46 NM_020822.2 c.2912_2913delinsAT/p.
(S971N)
268 M KCNT1 AD HT PAT – – – – MISS 0.59 3.54 NM_020822.2 c.1421G>T/p.R474L
PLAUSIBLE OLIGOGENIC INHERITANCE
13 M SCN1A AD HT MAT – B/LB rs121917956 0.002 MISS 0.58 4.89 NM_001165963.1 c.5749C>G/p.R1917G
CLCN2 AR,AD PAT – LB rs61729156 0.0068 MISS 0.53 2.83 NM_004366.5 c.203G>A/p.R68H
141 F SCN1A AD HT PAT – - rs1226308717 - MISS 0.54 5.44 NM_001165963.1 c.3376A>G/p.N1126D
SCN1A AD HT PAT – B/LB rs121917956 0.002 MISS 0.58 4.89 NM_001165963.1 c.5782C>G/p.R1928G
KCNT1 AD HT MAT – LB rs148162797 0.0008 MISS 0.57 −7.76 NM_020822.2 c.2220C>G/p.D740E
396 M SCN1A AD HT NA – B/LB rs121917956 0.002 MISS 0.58 4.89 NM_001165963.1 c.5749C>G/p.R1917G
CLCN2 AD HT NA – – rs202031742 1.5E-105 MISS 0.47 4.07 NM_004366.5 c.368C>T/p.S123F
1113 M HCN1 AD HT NA – – rs1462729387 4.1E-106 MISS 0.45 3.63 NM_021072.3 c.2269A>G/p.T757A
KCNT1 AD HT NA – CIP rs201156458 0.00028 MISS 0.40 4.08 NM_020822.2 c.3256G>A/p.G1086R
CACNA1H AD HT NA – LB rs187596702 0.00040 MISS 0.49 3.52 NM_021098.2 c.385G>A/p.G129S
968 F SCN1A AD HT MAT – – – – MISS 0.63 5.18 NM_001165963.1 c.2785C>T/ p.L929F
SLC12A5 AD HT NA – – – – MISS 0.59 3.47 NM_001134771.1 c.3343G>A/ p.E1115K
CACNA1A AD HT PAT – US rs200850308 8.2e-05 MISS 0.56 5.19 NM_023035.2 c.3179G>A
379 F SCN2A AD HT NA – CIP rs149987700 0.0003 MISS 0.56 5.29 NM_001040142.1 c.952G>A/p.E318K
SCN7A – – rs146072866 0.001 MISS 0.58 −0.257 NM_002976.3 c.2431A>G/p.S811G
DATA FROM PROGENITORS UNAVAILABLE: DE NOVO MUTATION STATUS UNCONFIRMED
1038 M SCN8A AD HT NA + – – – MISS 0.50 4.96 NM_014191.3 c.4633A>C/ p.T1545P
981 HCN1 AD HT NA – – – – MISS 0.58 5.37 NM_021072.3 c.715G>T p.V239L
738 F FOXG1 AD HT NA – – – – MISS 0.42 1.65 NM_005249.4 c.458G>T/p.G153V
887 M SCN1A AD HT NA – – rs777120925 7.49e-05 MISS 0.54 4.75 NM_001165963.1 c.1457C>G/p.A486G
CHRNA4 AD HT NA – – – – MISS 0.69 5.06 NM_000744.6 c.803C>T/p.P268L
523 F STXBP1 AD HT NA – P rs746172968 8,2E-106 MISS 0.53 5.27 NM_003165.3 c.1756G>A/p.D586N
SIK1 AD HT NA – – – – MISS 0.59 3.93 NM_001320643.1 c.1829G>Tp.R610L
676 M HECW2 AD HT NA – – – – MISS 0.46 2.43 NM_020760.2 c.3939C>G/p.I1313M
GABRB1 AD HT NA – – – – MISS 0.65 1.96 NM_000812.3 c.1017G>C/p.K339N
GABBR2 AD HT NA – – – – MISS 0.68 5.64 NM_005458.7 c.1858C>A/p.P620T
1029 M GRIA3 XLR HE NA – – – – MISS 0.41 5.52 NM_000828.4 c.793G>A/p.A265T
1099 M HECW2 AD HT NA – – – – MISS 0.44 5.10 NM_020760.2 c.900C>A/p.S300R
884 F ARHGEF9 XL HT NA – – – – MISS 0.49 5.46 NM_015185.2 c.1454G>T/p.G485V
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FIGURE 3 | Proportions of different types of inheritance (A), different types of variants (B), and the proportion of de novo events for the Iberian epilepsy cohort (C).
mutations (no microcephaly, no stereotypical movements, and
no regression) and therefore it was classified as of uncertain
significance. Similarly, variant G153V was not located in the
DNA-binding forkhead domain, in-silico predictions did not
support its deleteriousness, and the patient’s clinical picture did
not match that typically associated with FOXG1 mutations.
We detected 7 variants inCDKL5 (Figure 5D). The 4missense
CDKL5mutations were located in the N-terminal kinase domain,
which plays a particularly important role in brain function (Fehr
et al., 2013). All were the result of de novo mutations, except
for the variant detected in P1127, for which we observed very
high GERP and CONDEL scores and an associated phenotype
concordant with this disorder.
Four patients carried heterozygous missense variants in
GNAO1. Two of these patients carried the same variant. Our
analyses revealed that this gene was one of the best conserved,
with a low z-score (Figure 1) and a mean GERP score > 5
(Figure 2A). The phenotype of these 4 patients perfectly matched
that described for GNAO1-mutation carriers. Unfortunately, it
was not possible to test the de novo status of variant V301L in
P606. This variant is located in a highly conserved nucleotide.
Because the phenotype fitted well with that described for
GNAO1mutations, we classified this variant as likely pathogenic,
although familiar or functional studies will be required to support
this classification.
Variants With Special Characteristics
P186 and P884 carried a heterozygous missense variant in the
X-linked gene ARHGEF9. In P186, the variant was located in
the RhoGEF domain, which encodes the guanine nucleotide
exchange factor (GEF) activity of collybistin, while in P884
the variant was located in the C-terminal domain (Figure 5E).
While the CONDEL score for this variant was low, Human
Splicing Finder software revealed that this nucleotide change
promotes the emergence of a cryptic donor splice site ∼65%
stronger than the wild-type site, potentially affecting the
splicing of the last exon. Due to a lack of patient RNA
sample and samples from family members it was not possible
to determine the true involvement of this variant in the
patient’s phenotype.
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FIGURE 4 | Locations of variants found in our cohort in the proteins encoded by the following genes: (A) SCN1A; (B) SCN2A; (C) KCNQ2; (D) KCNA2; (E) KCNB1;
(F) KCNT1; (G) HCN1.
P685 carried a de novo missense variant in the BTB2 domain
of RHOBTB2 (Figure 5I). This variant was located in an amino
acid contiguous to that in which a de novo missense variant was
previously described in a female patient (Lopes et al., 2016) who
exhibited developmental stagnation at 6–9 months, coinciding
with the onset of generalized epilepsy and additional clinical
signs including Rett syndrome-like hand stereotypies, intense eye
communication, and sleep problems.
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FIGURE 5 | Locations of variants found in our cohort in the following genes: (A) ARX; (B) MECP2; (C) FOXG1; (D) CDKL5; (E) ARHGEF9; (F) DNM1; (G) SYN1; (H)
GRIN2A; (I) RhoBTB2; (J) MTOR. NTD, N-terminal domain; MBD, methyl CpG binding domain; TRD, transcriptional repression domain; NLS, nuclear localization
signal; CTD, C-terminal domain; FHD, forkhead domain.
CNVs Detected in Our Epilepsy Cohort
As mentioned in the introduction, genomic CNVs account
for a substantial proportion of the genetic burden in about
3% of patients with idiopathic epilepsies, and increase the
risk of idiopathic generalized epilepsy and a wide range of
neurodevelopmental disorders (Helbig et al., 2009; de Kovel
et al., 2010; Heinzen et al., 2010; Coe et al., 2012; Lal et al.,
2013; Møller et al., 2013). We detected 9 CNVs in our cohort.
One microdeletion in RBFOX1 encompassing exons 2 and 3
(12+3) was detected in P519. Figure 6 shows several of the
microdeletions reported for this gene. All affect exons at the
5′ end of the gene. Some are proven de novo mutations, while
others are inherited from an unaffected progenitor, indicating
variable penetrance. We found 2 microdeletions in GPHN
in patients P530 and P819, both of which were maternally
inherited. Deletions affecting GPHN exons are extremely rare
in the general population (Mefford et al., 2011; González
et al., 2013; Lionel et al., 2013; Dejanovic et al., 2014).
Previously described microdeletions in this gene are summarized
in Figure 6. The common overlapping region across the 10
deletions encompasses exons 3 and/or 5, which encode the G
domain of the gephyrin protein. G-domain trimerization is vital
for the formation of the hexagonal gephyrin oligomer scaffolds
required for stable GABA receptor clustering in postsynaptic
inhibitory neurons.
Variants of Unknown Significance
Variants for Which Additional Evidence Is Required to
Support Classification as Deleterious: Lack of
Familial Studies and/or Functional Validation
P248 presented secondary partial epilepsy that was unresponsive
to treatment, PMD, and Rett syndrome-like features, and was
found to carry 2 biallelic mutations in SCN9A. In this case it
would be necessary to demonstrate that the combined effects of
2 variants in opposite alleles give rise to the clinical phenotype.
This is the first case in which biallelic mutations in SCN9A have
been described.
In one (P523) of the 4 patients who carried variants in STXBP1
we detected a second missense variant in SIK1 (Table 1B). In
silico analysis predicted that both variants were likely deleterious
to the encoded protein. Unfortunately, it was not possible to
determine the contribution of these 2 variants to the patient’s
phenotype owing to the absence of DNA samples and clinical
histories for the patient’s parents.
The uncertain significance of the variant in TSC2
In P1144, a male with neonatal seizures characteristic of
tuberous sclerosis (TSC) who responded well to vigabatrin and
is progressing toward normality, we detected a missense variant
in TSC2. The very high GERP and CONDEL scores for this
gene indicate a high degree of sensitivity to variation (this
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FIGURE 6 | Microdeletions found in RBFOX1 and GPHN. Yellow, (Lionel et al.,
2013); green, (Dejanovic et al., 2014); blue, Fernández-Marmiesse (present
study).
gene had the second lowest z-score of all genes studied). These
findings support a functional impact of this variant. While the
majority of TSC patients are diagnosed during the first 15
months of life, the disease often goes unnoticed owing to the
wide phenotypic variability. Familial cases of TSC are caused by
germline mutations, but 70% of cases are the result of somatic
mutations (Lim et al., 2017). Familial transmission results in
mild-to-moderate disease that may not meet all diagnostic
criteria. In most such cases the first clinical sign is seizures.
All types of seizures can be observed in TSC patients. Two
thirds of cases begin with focal refractory epilepsy. TSC patients
have an increased risk of other neurocognitive deficits, including
ASD, ID, and mood alterations. A response to vigabatrin is
characteristic of these patients, but not distinctive. P1144 carried
a paternally inherited missense variant (L575P) in TSC2. We
received a blood sample from this patient a few days after her
birth and the discovery of the variant surprised her pediatrician,
since the patient’s seizures closely resembled those of TSC
patients. However, to date no cutaneous stigmas or tubers have
been detected. The patient’s father, who also carries the mutation,
underwent magnetic resonance imaging (MRI) but no tubers
were detected. P1144 has 2 siblings, both of whom were positive
for the TSC2 variant. Neither of the siblings display clinical
signs characteristic of TSC, but one is under study for short
height with no apparent cause and the other was born with
unilateral double ureter with grade IV reflux. MRI has been
prescribed for both siblings. Recent studies (Caylor et al., 2018;
Liu et al., 2018) have identified cases of TSC2mutations in which
the initial presentation consisted of seizures and describe the
incidental diagnosis of asymptomatic family members. Further
studies and follow-up are required to confirm the involvement
of this variant in the phenotypes of the family members. Given
the importance of a timely TSC diagnosis for appropriate clinical
management, these cases highlight the potential benefits of an
unbiased molecular diagnostic approach.
Variants in genes involved inTOR and GATOR complexes
Six of our patients carried variants in genes involved in TOR
and GATOR complexes. Brain somatic activating mutations in
MTOR have been described in patients with epilepsy caused
by focal cortical dysplasia (FCD) type II (Lim and Lee, 2016;
Møller et al., 2016). The variants described are located along all
exons of MTOR, although certain hotspots have been identified
(Figure 4J). Recently, the phenotypic spectrum associated with
germline variants in MTOR was extended to include milder
phenotypes than previously reported (Møller et al., 2016). Møller
et al. found 5 de novo germline mutations in MTOR in 6
individuals with variable epilepsy phenotypes (ranging from
focal to generalized) and brain malformations (ranging from
no malformation to macrocephaly). Moreover, they describe
a variant found in a mother-daughter pair with nocturnal
epilepsy of the frontal lobe. MTOR is therefore also a candidate
gene for epilepsy without cortical malformation. Our analyses
revealed that this gene was the second best conserved: its low z-
score implies a high sensitivity to missense variants (Figure 1).
Nonetheless, the CONDEL scores for the variants detected
in our cohort do not indicate a high level of deleteriousness
compared with controls (Figure 2). Two patients in our cohort
carried MTOR variants (Table 1B). In the first patient (P918),
we detected 2 biallelic missense variants in MTOR. The
patient’s mother, maternal uncle, and brother presented FS. The
probability of finding 2 missense rare variants in this gene is
3.98e−4. To our knowledge, there are no reports of epilepsy-
associated biallelic mutations in this gene. The second patient
(P1084) carried the missense K42N variant, which affects a highly
conserved nucleotide. A familial study revealed a paternal family
history of seizures, and indicated that the variant was inherited
from the patient’s father. However, we could not demonstrate
perfect cosegregation of the variant with the seizure phenotype,
indicating variable penetrance. Further genomic and functional
studies will be required to corroborate a relationship between
these variants and the patient’s epileptic phenotype.
Incomplete Penetrance
Except in cases of patients with a positive family history,
variants detected in dominant genes inherited from unaffected
progenitors or with a MAF > 0 were not classified as pathogenic
or likely pathogenic, in accordance with the guidelines of the
American College of Medical Genetics and Genomics (ACMG).
These variants (listed inTable 1B) are thus pending classification.
A role in the patient’s phenotype cannot be ruled out since
incomplete penetrance is not unusual in autosomal dominant
epileptic disorders, as described for example in patients with
PRRT2 frameshift mutations (Cloarec et al., 2012; Lee et al.,
2012) and mutations in SCN1A (Gennaro et al., 2003; Fukuma
et al., 2004; Kimura et al., 2005; Mancardi et al., 2006; Depienne
et al., 2009), SCN8A, KCNT1 (Møller et al., 2015), SLC12A5, or
DEPDC5 (Baulac, 2016). Potential explanations for incomplete
penetrance include parental mosaicism, oligogenic inheritance,
and the Knudson 2-hit mechanism (discussed below).
The Knudson 2-hit mechanism
Somatic mutational events in the brain are frequent (Hoang et al.,
2016). An individual can inherit one germinal variant from one
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progenitor and subsequent appearance during development of a
second variant in the same or another gene can have an additive
effect, giving rise to a clinical phenotype. In FCD, reports of brain
somatic mutations in genes involved in the mTORC1 pathway,
especially activating somatic MTOR variants, are increasingly
common (Poduri et al., 2013; Lim et al., 2015; Nakashima et al.,
2015; Mirzaa et al., 2016; Møller et al., 2016; Marsan and Baulac,
2018). The presence of loss-of-function mutations in DEPDC5
is the most common cause of familial focal epilepsies. However,
only a subset of patients among families withDEPDC5mutations
develop FCD (Baulac, 2016); other family members appear to
present non-lesional epilepsy. Ribierre et al. (2018) demonstrated
that a biallelic 2-hit (brain somatic and germline) mutational
mechanism in DEPDC5 causes focal epilepsy with FCD.
Digenic inheritance or modifier genes
Mutations in different ion-channel genes can exacerbate or
counteract epileptic phenotypes (Glasscock et al., 2007; Hawkins
et al., 2011; Klassen et al., 2011; Calhoun et al., 2017; Hasan
et al., 2017). These reports suggest that the co-occurrence of 2
mutations in distinct genes that are independently innocuous can
give rise to a clinical phenotype and help explain the incomplete
penetrance described formany epilepsy-related genes. Functional
studies and/or further reports of similar cases will obviously be
required to confirm this hypothesis.
Our cohort included several potential examples of digenic
inheritance. For example, 3 patients in our cohort carried variant
R1928G in SCN1A (frequency, 0.0026 in 1000G). In 2 cases (P13
with EIEE and P396 with Dravet syndrome and severe ID) this
variant co-existed with a rare missense variant in CLCN2 (R68H
and S123F, respectively). Neither of these CLCN2 variants are
recorded in PVDB or in 1344 Ib-chr, and the first was confirmed
to be in trans with the R1928G variant. The probability of finding
2 rare missense variants simultaneously in both genes is 3.99e−4.
The CLCN2 encodes the ClC-2 chloride channel. Underscoring
the importance of this channel in the brain, biallelic mutations
in this gene are associated with leukoencephalopathy with
ataxia (MIM_615651). Although there is some evidence linking
CLCN2mutations to susceptibility to epilepsy, these data remain
controversial, and these cases could alternatively be explained by
undetected digenic inheritance (Sander et al., 2000; Haug et al.,
2003; Kleefuss-Lie et al., 2009; Saint-Martin et al., 2009). In the
third case (patient P141), the SCN1A variant was present in cis
with a second SCN1A variant and in trans with a KCNT1 variant
(Prob = 1.99e−3). This patient presented neonatal refractory
epilepsy (Otahara syndrome), central coordination disturbance,
peculiar phenotype, hepatomegaly, and ventriculomegaly.
Another example was the patient P1113, a male with seizures
and GDD, carrying a missense KCNT1 variant, with a frequency
in public variant databases that was incompatible with dominant
inheritance with full penetrance, accompanied by 2 other ion
channel variants in HCN1 and CACNA1H. In this case further
functional studies will be required to determine the variant’s role
in the patient’s phenotype (Prob∼ 0).
P676, in addition to carrying a variant in GABRB1,
carried another variant in GABBR2 (Table 1B), a gene also
implicated in EIEE (EuroEPINOMICS-RES Consortium, 2014).
Unfortunately, this patient lives in an institution and their
parents could not be contacted to perform a familial study.
Digenic inheritance was clearer in the case of 2 Portuguese
siblings, P501 and P968, who presented very different forms of
epilepsy. One had a clear molecular diagnosis for a recessive gene
(SLC12A5) and carried a maternally inherited SCN1A variant.
The patient’s sister, who had a milder phenotype consistent
with absence epilepsy that was well-controlled with valproate,
carried a combination of inherited heterozygous variants in
genes encoding ion channels: SCN1A (maternal), CACNA1A
(paternal), and SLC12A5. In individuals of French-Canadian
origin, the SLC12A5 missense variants R952H and R1049C
in heterozygosity have been shown to predispose carriers to
generalized epilepsy (Kahle et al., 2014; Puskarjov et al., 2014). In
those studies, in vitro functional expression studies revealed that
these variants impair SLC12A5 function. Moreover, in several
cases the variants were inherited from an unaffected parent,
consistent with incomplete penetrance. Further evidence from
functional studies in mouse models will be required to confirm
cases of proposed digenic inheritance.
Limitations of the Study
A limitation of the targeted resequencing approach is that,
unlike WES, it cannot detect novel epilepsy-associated genes.
Furthermore, unlike WGS it does not allow detection of
mutations in intronic sequences or non-coding RNAs with
transcriptional regulation roles which together correspond
to 80% of human genome according to ENCODE Project
Consortium 2012 (The ENCODE Project Consortium, 2012).
Moreover, our approach can detect neither balanced structural
variants nor CNVs outside coding regions, both of which can
change the regulatory landscape of developmental genes and alter
the delicate balance between transcriptional enhancers, silencers,
and insulators (Conrad et al., 2010; Spielmann and Klopocki,
2013). Epimutations, which may account for disease in ∼20%
of neurodevelopmental disorders and congenital anomalies
(Barbosa et al., 2018) are also undetectable with this technology.
A final limitation of our approach is that mutations in somatic
mosaicism may also go undetected in blood samples and it
has been shown that somatic mutational events in brain tissue
are frequent (Hoang et al., 2016) and a high frequency of
mosaic pathogenic variants in epilepsy-associated genes has been
demonstrated (Stosser et al., 2018).
CONCLUSIONS
• Well-optimized targeted exome sequencing of a large high
number of genes with high mean coverage can be highly
beneficial to clinical specialists and to pediatric epileptic
patients and their families. By using this approach in our
cohort, we were able to establish a genetic diagnosis in
∼42% of cases. This in turn alleviates parental anxiety
and guilt, helps identify at-risk family members, and can
facilitates reproductive decision-making. Furthermore, it
provides parents with access to a community with shared
experiences, limits the need for counterproductive tests and
treatments, and enables selection of the most appropriate
antiepileptic therapy.
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• The length of the mean diagnostic delay in our cohort (∼6
years, measured from the time of onset of clinical signs
until molecular diagnosis) underscores the importance of
implementing tests of this kind as first-tier diagnostic tools for
epilepsy patients.
• To take into account the varying mutational sensitivities of
epilepsy-related genes, their specific mutational architecture,
the in-silico prediction of missense variants (GERP and
CONDEL) and filtering variants using a large, well-
characterized database of the patient’s population is essential
to ensure optimal prioritization of the variants detected.
• CNVs account for a considerable percentage of the mutational
load in epilepsies (as much as nonsense and frameshift
variants). If the mean coverage achieved using our panel had
been lower (as is the case with many diagnostic panels), this
specific source of mutations would have gone unnoticed.
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